Authors: Brecher M and Huizar K. 
Title: Quetiapine monotherapy for the treatment of mania (STAMP 1). 
Reference: European Neuropsychopharmacology. The Journal of the European College of Neuropsychopharmacology 2003;13(Suppl 4):S337.
Purpose: To evaluate the safety and efficacy of quetiapine monotherapy for the treatment of mania associated with bipolar disorder.
Study design: Randomized, double-blinded, placebo-controlled study. 
Follow up: 12 weeks.
Patients: 302 patients (102 quetiapine, 101 placebo, and 99 haloperidol).
Treatment: Quetiapine titrated to a maximum of 800 mg/day, haloperidol titrated to a maximum of 8 mg/day, or placebo. 
Results: Quetiapine and haloperidol were associated with a significantly greater reduction in YMRS score compared with placebo. Response rates were 61% for quetiapine versus 39% for placebo. EPS were consistently higher in the haloperidol group, as were discontinuations due to adverse events, compared with quentipine or placebo.